Royal Bank Of Canada Ionis Pharmaceuticals Inc Call Options Transaction History

Royal Bank Of Canada

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$40.06 - $51.86 $4.47 Million - $5.79 Million	-111,600 Reduced 64.03%	62,700 $2.51 Million
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $5.44 Million - $7.12 Million	149,300 Added 597.2%	174,300 $8.31 Million
Q1 2024 Nov 05, 2024	SELL	$42.03 - $53.55 $6.28 Million - $8 Million	-149,300 Reduced 85.66%	25,000 $1.08 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $1.03 Million - $1.31 Million	24,500 Added 4900.0%	25,000 $1.08 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $19,250 - $23,565	500 New	500 $22,000

404

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.02B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.